Nifty Pharma Jumps 1.48% as US Biosecure Act Passage Lifts Sentiment; Divi’s Laboratories, Piramal Pharma Rise

Mumbai, October 10, 2025: The NIFTY PHARMA index is seeing strong investor interest today. As of 1:50 PM, the index was up 1.30%, or 284.25 points, trading at 22,220.45. So far, it has moved within a range of 21,849.55 to 22,324.60. The gains are being led by Divi’s Laboratories and Piramal Pharma, as positive sentiment around the passage of the US Biosecure Act boosts investor confidence in Indian pharmaceutical and contract manufacturing stocks.

Top Gainers And Losers (As of 1.55 PM)

As of 1:55 PM, 17 stocks in the NIFTY PHARMA index were in the green, while 3 were in the red. Leading the gains was Divi’s Laboratories, up 5.15% at ₹6,447.50, followed by Cipla, up 2.89% at ₹1,556.90, Piramal Pharma, up 2.80%, and Wockhardt, up 2.06%.

Top losers include Mankind Pharma, down by 0.10%, to ₹2,476.80, Alkem Laboratories, down by 0.28% at ₹5,465.00, and Gland Pharma, down by 1.42% at ₹1,925.00.

The US Senate Pass the National Defense Authorization Act

The strong demand in the index is due to the US Senate passing the National Defense Authorization Act, which also includes the Biosecure Act. This law restricts the US government from buying biotech and pharmaceutical services or equipment from certain foreign companies. Because of this, analysts believe Indian CDMO (Contract Development & Manufacturing) companies and generic drug exporters may benefit, since the US will look for alternative providers. Companies like Divi’s Laboratories, Laurus Labs, and Aurobindo Pharma are seen as possible winners if US pharma sourcing shifts away from banned foreign suppliers.

REF: https://www.nseindia.com/market-data/live-equity-market?symbol=NIFTY PHARMA

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations